Chemed Reports Q3 Revenue Up 3.1% to $624.9 Million

Reuters10-29

Chemed Reports Q3 Revenue Up 3.1% to $624.9 Million

Chemed Corporation reported third-quarter 2025 results, with consolidated revenue increasing 3.1% to $624.9 million compared to the prior-year period. The VITAS segment recorded net patient revenue of $407.7 million, up 4.2%, and an average daily census of 22,327, up 2.5%. As of September 30, 2025, Chemed had total cash and cash equivalents of $129.8 million and no current or long-term debt. During the quarter, the company repurchased 407,500 shares for $180.8 million, with a remaining share repurchase authorization of $301.8 million. Chemed has approximately $404.5 million undrawn borrowing capacity under its credit agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemed Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9562588-en) on October 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579035991?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 04:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579035991","market":"us","top_or_hot":-1,"title":"Chemed Reports Q3 Revenue Up 3.1% to $624.9 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chemed Reports Q3 Revenue Up 3.1% to $624.9 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Chemed Corporation reported third-quarter 2025 results, with consolidated revenue increasing 3.1% to $624.9 million compared to the prior-year period. The VITAS segment recorded net patient revenue of $407.7 million, up 4.2%, and an average daily census of 22,327, up 2.5%. As of September 30, 2025, Chemed had total cash and cash equivalents of $129.8 million and no current or long-term debt. During the quarter, the company repurchased 407,500 shares for $180.8 million, with a remaining share repurchase authorization of $301.8 million. Chemed has approximately $404.5 million undrawn borrowing capacity under its credit agreement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemed Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9562588-en) on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chemed Reports Q3 Revenue Up 3.1% to $624.9 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemed Reports Q3 Revenue Up 3.1% to $624.9 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-29 04:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chemed Reports Q3 Revenue Up 3.1% to $624.9 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Chemed Corporation reported third-quarter 2025 results, with consolidated revenue increasing 3.1% to $624.9 million compared to the prior-year period. The VITAS segment recorded net patient revenue of $407.7 million, up 4.2%, and an average daily census of 22,327, up 2.5%. As of September 30, 2025, Chemed had total cash and cash equivalents of $129.8 million and no current or long-term debt. During the quarter, the company repurchased 407,500 shares for $180.8 million, with a remaining share repurchase authorization of $301.8 million. Chemed has approximately $404.5 million undrawn borrowing capacity under its credit agreement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemed Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9562588-en) on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1721427968.SGD","symbol_name":"BNP PARIBAS AQUA \"CRH\" (SGDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL8SNXdr:1","article_id":"2579035991","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579035991","pubTimestamp":1761682577,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Chemed Corporation reported third-quarter 2025 results, with consolidated revenue increasing 3.1% to $624.9 million compared to the prior-year period. The VITAS segment recorded net patient revenue of $407.7 million, up 4.2%, and an average daily census of 22,327, up 2.5%. As of September 30, 2025, Chemed had total cash and cash equivalents of $129.8 million and no current or long-term debt. During the quarter, the company repurchased 407,500 shares for $180.8 million, with a remaining share repurchase authorization of $301.8 million. Chemed has approximately $404.5 million undrawn borrowing capacity under its credit agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemed Corporation published the original content used to gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1721427968.SGD":"BNP PARIBAS AQUA \"CRH\" (SGDHDG) INC","LU2413666004.HKD":"BNP PARIBAS AQUA \"CRH\" (HKDHDG) INC","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","LU1596574779.USD":"BNP PARIBAS AQUA \"C\" (USDHDG) ACC","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU1543694498.USD":"法巴水资源基金RH MD Dis","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","LU1620156130.USD":"BNP PARIBAS AQUA \"C\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","CHE":"Chemed Corp","LU2413665964.HKD":"BNP PARIBAS AQUA \"C\" (HKD) ACC","BK4196":"保健护理服务","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","LU1620156213.USD":"BNP PARIBAS AQUA \"C\" (USD) INC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Chemed报告第三季度收入增长3.1%至6.249亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHE":0.9,"NDAQ":0.9},"content_text":"Chemed Reports Q3 Revenue Up 3.1% to $624.9 Million\n    \n\n        Chemed Corporation reported third-quarter 2025 results, with consolidated revenue increasing 3.1% to $624.9 million compared to the prior-year period. The VITAS segment recorded net patient revenue of $407.7 million, up 4.2%, and an average daily census of 22,327, up 2.5%. As of September 30, 2025, Chemed had total cash and cash equivalents of $129.8 million and no current or long-term debt. During the quarter, the company repurchased 407,500 shares for $180.8 million, with a remaining share repurchase authorization of $301.8 million. Chemed has approximately $404.5 million undrawn borrowing capacity under its credit agreement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemed Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9562588-en) on October 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579035991","isCrawlerRequest":true}